RayPilot HypoCath_ Next Generation real-time tumor tracking for radiotherapy against prostate cancer

Reference number 2018-04732
Coordinator MICROPOS MEDICAL AB (PUBL) - Micropos Medical AB
Funding from Vinnova SEK 500 000
Project duration December 2018 - May 2019
Status Ongoing

Purpose and goal

The overall goal of this project is to develop an enhanced (non-invasive) version of our RayPilot solution and realise its international commercialisation. The work plan split into 2 Phases: Phase 1 (for this application), where we will dedicate 4 months to complete the technical, commercial, and financial feasibility analysis of RayPilot® HypoCath Phase 2 (later funding application), with 18 months to conduct the technical developments and prepare the international commercialisation of the upgraded product at EU level, our focus during the initial years.

Expected results and effects

The commercialisation of HypoCath will represent significant growth to Micropos, generating new IP, additional €6.63 million revenues by 2024, and at least 15 new direct jobs.

Planned approach and implementation

Phase 1, where we will dedicate 4 months to complete the technical, commercial, and financial feasibility analysis of RayPilot® HypoCath. See further on Page 5 in attached PDF-file with objectives in Table 2 and activities detailed in Section 3, Work Plan.

External links

Micropos Medical´s hemsida för ytterligare information om RayPilot systemet

The project description has been provided by the project members themselves and the text has not been examined by our editors.